Navigation Links
Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
Date:9/16/2009

EAST BRUNSWICK, N.J. Sept. 16 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that on September 14, 2009, the Company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) received by Savient on July 31, 2009 regarding the Company's Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy.

Based on the results of this meeting with the FDA, Savient believes that the FDA supports its approach to resolve all issues cited in the CRL. The meeting also confirmed that the FDA does not expect further clinical trials to be required as a result of Savient's reversion to the original manufacturing process to produce the Phase 3 clinical trial material for KRYSTEXXA, provided that no significant differences are observed between the material produced with the validated Phase 3 process and the Phase 3 clinical trial material. Savient, therefore, continues to believe that it can meet its previously discussed timeline of filing the resubmission in response to the CRL in early 2010.

"We are encouraged by the FDA's continuing collegial and collaborative dialogue in providing guidance to assist us in establishing the path forward to our resubmission for KRYSTEXXA," stated Paul Hamelin, President of Savient Pharmaceuticals. "We are grateful to the FDA for granting us this meeting so quickly and appreciate the considerable time and effort devoted by the FDA reviewers in evaluating our pre-meeting package and in providing very valuable feedback and guidance."

In response to the CRL, Savient requested and was granted the Type A meeting with the FDA to disc
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
2. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
3. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
4. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
5. Savient Announces Appointment of David Gionco as Chief Financial Officer
6. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
7. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
8. Savient Submits Biologics License Application (BLA) for pegloticase
9. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
10. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
11. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 A ... accelerated partial breast irradiation (APBI) via interstitial brachytherapy ... with positive lymph nodes could be suitable to ... Oncology (ASTRO) guidelines place these patients in the ... at the 2014 ASTRO meeting, Beaumont Health System,s ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... offer and sell shares of its Common Stock and ... underwritten public offerings.  The Series A Convertible Preferred Stock ... Stock, provided that conversion will be prohibited if, as ... own more than 4.99% of the Common Stock then ...
(Date:9/17/2014)... SAN DIEGO and PRINCETON, N.J. ... Inc. (NASDAQ: OTCQB:AEMD), the pioneer in developing targeted therapeutic ... conditions, and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), ... the 2014 Exosomes & SingleCell Analysis Summit. ... of Exosome Sciences will give a presentation entitled: "Exosomes: ...
(Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. (NASDAQ: ... and marketer of patent protected regenerative biomaterials and ... publication of another peer-reviewed clinical study.    ... Multi-center Randomized Controlled Clinical Trial Evaluating the Use ... Allografts and Multi-layer Compression Therapy vs. Multi-layer Compression ...
Breaking Biology Technology:Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Oncothyreon Announces Proposed Public Offerings 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4
... Madison, Wis. - MyWeather LLC has ... chief marketing officer. , ,Baird went to Carleton College ... former Wisconsin Governor Martin Schreiber. He has served as ... a major K-12 technology company; vice president of sales ...
... Doyle announced that the Department of Commerce's Technology ... seed capital to Wisconsin high-tech companies of fewer than ... GenTel BioSurfaces, Inc. , helping to finance their biochip ... a microscope slide that contain multiple testing factors for ...
... The old Institute of Paper Chemistry might have left ... can still feel the void. , ,Organizers of the ... filling that void Wednesday with the PTTC's grand opening in ... paper-producing state, rolling out more than 6.4 million tons of ...
Cached Biology Technology:Paper technology transfer center opens in Green Bay 2Paper technology transfer center opens in Green Bay 3
(Date:9/16/2014)... Columbia Center for Children,s Environmental Health at the Mailman ... an association between childhood asthma and prenatal exposure to ... products. Results appear online in the journal Environmental ... exposed during pregnancy to higher levels of the chemicals, ... 72 percent and 78 percent increase in risk of ...
(Date:9/16/2014)... September 13, 2014. The fire is human-caused and ... acres in size and is mostly being fueled by ... Monday night due to higher humidity. Yesterday (8/15), ... to construct a fireline on the West and North sides ... the fire: , 7 20-person Crews, 4 Hot Shot Crews, ...
(Date:9/16/2014)... diameter chunk of rock hit the Yukatan peninsula near the ... of 100 teratons of TNT. It left a crater more ... earthquakes and volcanism are widely accepted to have wiped out ... mammals. But what happened to the plants on which the ... the University of Arizona reveals that the meteorite impact that ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... 19, 2013) Columbia University College of Physicians ... announced that the Mortimer D. Sackler, M.D. Prize ... awarded to Carla Shatz, PhD, the Sapp Family ... Palo Alto, California. Dr. Shatz,s work has advanced ...
... Researchers at Plymouth University, UK, believe that findings from ... between the Early Jurassic era of 180 million years ... Through geology and palaeontology, they,ve shown how higher ... marine communities, and that while the Jurassic seas eventually ...
... elementary school students are expected to attend an INSECT EXPO ... PM on Monday, February 25 at the start of the ... Society of America (ESA), which will be held February 25-28 ... This free educational event will reinforce students, science ...
Cached Biology News:Pioneer in neural development honored with the Mortimer D. Sackler, M.D. Prize 2Pioneer in neural development honored with the Mortimer D. Sackler, M.D. Prize 3Pioneer in neural development honored with the Mortimer D. Sackler, M.D. Prize 4Jurassic records warn of risk to marine life from global warming 2
GOAT ANTI PPP2R5B...
... Molecular Probes Fc OxyBURST Green reagent ... Simons of Boston University to permit measurement ... internalization and the subsequent oxidative burst directly ... assay reagent consists of bovine serum albumin ...
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
MOUSE ANTI RAT RT1Bu / MOUSE Ia:BIOTIN Immunogen: Rat thymocyte membrane glycoproteins...
Biology Products: